Perhaps the world’s most famous aging researcher, Dr. David Sinclair of Harvard University, recently revealed that his lab is working on an advanced method for hair restoration.
THE SINCLAIR LAB AT HARVARD MEDICAL SCHOOL HAIR GROWTH RESEARCH
Located in Boston, MA, The Sinclair Lab conducts cutting-edge research on the mechanisms of biological aging. The laboratory’s namesake, Dr. David Sinclair, has become a poster child for the anti-aging industry, and possibly the world’s most famous scientist due to society’s growing interest in longevity. He’s made several appearances on the Joe Rogan Podcast including an episode posted on June 18, 2021. Sinclair is widely known for his research on NAD+, a coenzyme that plays a major role in cellular metabolism but degrades as people age. The Harvard professor is widely known for his intake of NMN, a precursor to NAD+ which can be taken as a dietary supplement, similar to NR.
While many people anticipate David Sinclair to commercialize a pharmaceutical super NAD+ booster or even a gene therapy which “reprograms” cells to restore eyesight, none would predict that Sinclair may potentially solve hair loss by finding a new way to regrow hair. Until now, at least. This past week on Twitter, Sinclair shared the recent study written by Ralf Paus and Desmond Tobin, among others, which showed that hair greying is reversible and linked to stress levels in human tissue. He wrote in his own caption “In the future losing your hair or going grey will be a choice.” This prompted to me to inquire about his own interest in the subject, to which he was kind enough to respond to, see below.
A formidable new entity has now publicly entered the hair regeneration race. It’s still a bit of a mystery as to exactly what type of therapy the Sinclair Lab is developing; on one hand it sounds as if they are creating a gene-related therapy similar to Turn Biotechnologies, and on the other it sounds like they may be “cloning” hair follicles à la Dr. Tsuji. Either way, this is a significant news find. Sinclair would be quick to translate this technology into a clinical setting once the research has been validated.
